Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

JOURNAL ARTICLE published July 2018 in The Lancet Oncology

Authors: Andrew X Zhu | Richard S Finn | Julien Edeline | Stephane Cattan | Sadahisa Ogasawara | Daniel Palmer | Chris Verslype | Vittorina Zagonel | Laetitia Fartoux | Arndt Vogel | Debashis Sarker | Gontran Verset | Stephen L Chan | Jennifer Knox | Bruno Daniele | Andrea L Webber | Scot W Ebbinghaus | Junshui Ma | Abby B Siegel | Ann-Lii Cheng | Masatoshi Kudo | Angela Alistar | Jamil Asselah | Jean-Frederic Blanc | Ivan Borbath | Timothy Cannon | Ki Chung | Allen Cohn | David P Cosgrove | Nevena Damjanov | Mukul Gupta | Yoshivasu Karino | Mark Karwal | Andreas Kaubisch | Robin Kelley | Jena-Luc Van Laethem | Timothy Larson | James Lee | Daneng Li | Atisha Manhas | Gulam Abbas Manji | Kazushi Numata | Benjamin Parsons | Andrew S. Paulson | Carmine Pinto | Robert Ramirez | Suresh Ratnam | Magnus Rizell | Olivier Rosmorduc | Yvonne Sada | Yutaka Sasaki | Per I Stal | Simone Strasser | Joerg Trojan | Gina Vaccaro | Hans Van Vlierberghe | Alan Weiss | Karl-Heinz Weiss | Tatsuya Yamashita